Download presentation
Presentation is loading. Please wait.
Published byMilagros Toro Modified over 5 years ago
1
The 7th East African Health and Scientific Conference
Use of Electronic devices in Establishing the Risk factors for Multidrug-Resistant Tuberculosis in Bujumbura City, Burundi, 2018 Dr. Alexis Niyomwungere National Institute for Public Health Bujumbura, Burundi
2
Background Tuberculosis (TB) is the leading cause of death infectious disease and the 9th leading cause of death worldwide (WHO Global Report 2018) Among challenges of controlling TB is development of drug-resistance Multidrug resistant Tuberculosis (MDR-TB); type of TB transmitted by M. tuberculosis strains that resist to Rifampicin and Isoniazid the two most powerful anti-TB drugs MDR-TB is becoming a global threat ; affect both new persons and previously TB treated persons (WHO Global Report 2018) Prevention measures (CDC TB Prevention, 2017) Early diagnosis & immediate initiation of treatment Treatment adherence Avoid exposure to known MDR-TB patients In 2017, there were an estimated 10.4 million new tuberculosis (TB) cases (WHO Global Report 2018) Around 600,000 TB cases developed first-line drug resistance or MDR/RR-TB with MDR-TB accounting for 82% (WHO global TB report,2018) In 2016, Burundi reported 2.6% of new cases of MDR-TB and 13% of cases previously treated (WHO Global TB report , 2017) Burundi is not among top 30 countries with highest MDR-TB burden
3
Problem Statement Justification
Compared to 2016 and 2017, Burundi reported a reduction of MDR/RR-TB incidence in 2018, however the MDR- TB rate did not decrease (Global TB report 2016, 2017, 2018) There are still deaths (average CFR of 7.5% per year for the last 7 years) due to MDR/RR-TB in Burundi (NTLCP annual report 2017) On average, 52.7% (SD=12.8%) of reported MDR-TB cases for the last 7 years were from Bujumbura City (MDR-TB surveillance report, ) Despite the active surveillance of MDR-TB cases and strict follow up of confirmed MDR-TB patient and contact in Burundi; Bujumbura continue having an increased number of MDR-TB patients although overall national incidence has decreased (MDR-TB surveillance report, 2017 and WHO Global report 2018) Very few studies performed looking for determinants of MDR-TB in Bujumbura To reduce this MDR-TB incidence, identification of MDR-TB determinants will facilitate the implementation of evidence based interventions strategies that are best suited for local situation Justification
4
Objectives General Objective Specific objectives
To establish factors associated with Multi-Drug Resistant Tuberculosis in Bujumbura City, Burundi Specific objectives To determine Socio-demographic factors associated with MDR-TB in Bujumbura City To determine behavioral factors associated with MDR-TB in Bujumbura City. To determine clinical and previous TB history factors associated with MDR-TB in Bujumbura City.
5
Methods Study Site: Bujumbura City is Burundi’s capital city
Largest city with a population of 692,331 (ISTEEBU, 2016) Urban and peri-urban setups with informal settlements The poverty index of the city is 28.7% Three health districts and National Anti-TB center Thirteen Centers for TB Diagnosis and Treatment (CDTs) All MDR-TB patients are referred to the National center for MDR-TB care: admission for the first 4 months Study Design: Unmatched case control study Hospital cases and controls Study population: Patients from Bujumbura City diagnosed with MDR- TB
6
Inclusion and Exclusion criteria
Inclusion criteria Cases: Living in Bujumbura City, Confirmed by GeneXpert to be MTB-rifampicin resistant and with culture and drug susceptibility testing confirmed to have MTB strain resistant to Isoniazid, Patient must be on treatment and signed the consent form Controls: Laboratory confirmed to have pulmonary TB On sixth month of treatment of pulmonary TB with first line anti-TB drugs and accept to sign the consent form Exclusion criteria Controls: Presence of MTB organism after 5th month of treatment Cases and Controls: A Patient with extra pulmonary TB A Patient diagnosed and/or treated in Bujumbura City but not resident
7
Sample Size The sample size was calculated using Fleiss formula(2013)
Assumptions: alpha level of significance (Zα/2) of 5%, power (Z1-β) or percentage of detection of 80%, ratio (r) of one case to two controls, An odds ratio (OR) of 3 An estimated proportion (p2) of controls not vaccinated of 17.4% (n1 = number of cases and n2 = number of controls Sample size= 150 (50 cases and 100 controls)
8
Sampling Procedures From National MDR-TB register (Cases selection);
List all patients on treatment from Bujumbura City Using Ms. Excel, randomly generated a list of 50 patients Generated a list of CDTs from which they were referred From the TB register in CDT (Controls selection), Generated a list of TB patients on sixth month of treatment Based on the number of cases per CDT, 2 controls per cases were recruited Systematic random sampling method was used: calculated K = N/n (N: number of TB patients received per day for treatment and n: number of controls needed from that health facility) Each Kth patient was recruited, the first randomly selected between 1 and K we looked at the number of TB patients received per day for treatment (N), and based on the number of controls needed from that health facility (n), calculate the interval (K). K = N/n. Then each Kth patients who met control definition was selected. The first was selected randomly between 1 and K using Ms Excel formula for simple random sampling
9
Data Collection and Analysis
We collected data from March ̶ May 2018 with Electronic tablets Standardized structured questionnaire administered Variables collected; Socio-demographic characteristics: Demographics, distance and mean time to CDT, Clinical characteristics including laboratory information TB/VIH coinfection, diabetes, vaccination, bacillary load, TB type Behavioral variables: Smoking and SHS, alcohol intake, drug abuse, imprisonment Medical history of TB: TB in family, contact with MDR-TB, TB treatment history, treatment adherence Analysis was performed with Epi InfoTM 7.0 and STATA version 12 Descriptive analysis done and Crude odds ratios calculated at bivariate analysis; Factors with P-value ≤0.25 used at multivariate Unconditional forward selection logistic regression; Independent factors associated with MDR-TB Variables with p-values ≤0.05 considered statistically significant and reported in the final model
10
Ethical Approval Scientific and ethical clearance obtained from Institutional Research and Ethics Committee (FAN: IREC 2054) Authorization obtained from Burundi Ministry of Health to conduct the investigation and access to the patients records (Ref. 633/04/DGSSLS/2018) Written consent to participants before interview Questionnaires were kept in a locked cabinet Data were stored in password protected computers
11
RESULTS
12
Socio-demographic and behavioral factors associated with MDR-TB, Bujumbura City, Burundi, 2018
Exposure variables Cases (N=50) Controls (N=100) cOR* (95% CI**) P-value n (%) Contact with MDR-TB patient Yes 11 (22) 2 (2) 13.82 (2.93 – 65.22) 0.003 No 39 (78) 98 (98) Ref. Sex Female 20 (40) 21 (21) 2.51 (1.19 – 5.27) 0.014 Male 30 (60) 79 (79) Living with MDR-TB person in the family within same house 38 (76) 58 (58) 2.29 (1.07 – 4.91) 0.033 12 (24) 42 (42) Ref Duration of window open per day ≤6 hours 12 (31.6) 35 (57.4) 2.9 (1.24 – 6.83) >6 hours 26 (68.4) 26 (42.6) Open window in the house 38 (82.6) 61 (67.0) 1.89 (0.97 – 5.63) 0.058 8 ((17.4) 30 (30.0)
13
Clinical and Medical TB history factors associated with MDR-TB, Bujumbura City, Burundi, 2018
Exposure variables Cases (N=50) Controls (N=100) cOR* (95% CI**) P-value n (%) Previously treated for TB Yes 29 (58) 20 (20) 5.52 (2.62 – 11.64) <0.001 No 21 (42) 80 (80) Ref. Previous TB treatment outcome Relapse 17 (17) 4.50 (2.02 – 9.94) 0.005 Treatment failure 6 (12) 1 (1) 21.82 (2.49 – ) Lost to follow up 1 (2) 2 (2) 1.82 (0.16 – 20.99) 0.632 New case 22 (44) Treatment interruption 45 (90) 70 (70) 0.25 (0.09 – 0.72) 0.009 5 (10) 30 (30) HIV status Positive 14 (28) 8 (8) 4.47 (1.73 – 11.57) 0.002 Negative 36 (72) 92 (92) Treatment change before 44 (88) 98 (98) 0.15 (0.02 – 0.77) 0.023 Ref
14
Independent factors associated with MDR-TB, Bujumbura City, Burundi, 2018
Cases (n=50) Controls (n=100) cOR* (95% CI**) aOR*** (95% CI) P-value Previously treated for tuberculosis 29 (58) 20 (20) 5.52 (2.62 – 11.64) 5.37 (3.34 – 12.30 <0.001 Contact MDR-TB patient 11 (22) 2 (2) 13.82 (2.93 – 65.22) 12.32 (2.93 – 65.22) 0.003 Treatment change 44 (88) 98 (98) 0.15 (0.02 – 0.77) 0.13 (0.02 – 0.75) 0.023 HIV Positive 14 (28) 8 (8) 4.47 (1.73 – 11.57) 2.50 (0.77 – 8.15) 0.129 Living with MDR-TB person in family 38 (76) 58 (58) 2.29 (1.07 – 4.91) 2.51 (1.03 – 6.11) 0.042 *cOR= crude Odds Ratio, **CI= Confidence Interval, ***aOR= adjusted Odds Ratio
15
Discussion 1/2 Among socio demographic factors, Contact with a MDR-TB patient and living with an MDR-TB patient in the family had a higher odds for developing MDR-TB, Continuous contact lead to continuous exposure to resistant strain. Contrast to others where continuous contact with MDR-TB patient had a lower odds tending to be protective (Mulu et al., 2015) The study had a small proportion of primary MDR-TB cases In our study, no behavioral factor was independently associated with the MDR-TB although having a house window opened less than 6 hours per day had a strong association Increased sensitization on TB and MDR-TB in the City Similar findings by Weyenga et al., 2009, As clinical factor, HIV positive had higher odds of getting MDR-TB compared to HIV negative although not statistically significant Majority of case patients (75%) in our study had secondary MDR-TB Similar to findings in Ethiopia and in a systematic review of published paper (Espinal et al., 2001; Suchindran et al., 2009; Wells et al., 2007; Workicho et al., 2017a) Contrast with Weyenga et al., 2009 and Mulu et al., 2015
16
Discussion 2/2 Limitations
Previously treated for TB had a higher odds of developing MDR-TB compared to new cases of MDR Development of strains resistant to drugs by the bacteria due to the length of the treatment Compares to studies done in several part of the world and similar to findings from a population based surveillance network over 11 countries (Espinal et al., 2001) However our findings, high proportion of new MDR-TB cases (42%) compared to Marahatta et al., findings (5.5%) Change of treatment in the previous episodes showed a protective effect in our findings, Shift from the old regimen to the new regimen in Similar findings with Demile et al., 2018 Limitations Case control study- likelihood that participants did not recall the true information Cases and controls on treatment Professional and well-trained interviewers Using a structured questionnaire Link questions to events The longer the treatment, the more the subject to some interruption, poor adherence of the patient, improper drug regimen A population-based review of international drug resistance surveillance network over 11 countries showed that an association between the length of treatment and drug resistance could be the reflection of longer treatment (Espinal et al., 2001) This was a positive change towards a new regimen that was approved to have more advantages (old regimen of twelve months of treatment to the new regimen of nine months)
17
Conclusion and Recommendations
Tablets quickly collect data and make it easy and ready for analysis Contact with an MDR-TB patient and living with MDR-TB patient in the family and history of previous treatment were the major sociodemographic and clinical and medical TB treatment history determinants for contracting multidrug-resistant tuberculosis There was no behavioral factors associated with the development of the MDR-TB Recommendations Encourage the use of tablets for data collection The TB control program should trace and screen all contacts of MDR-TB patients; revisit the policy on tuberculosis treatment adherence and basic TB infection control practice within the MDR-TB patients. Further study on MDR-TB patient pathway could show when the contact transmission happen
18
Acknowledgements Burundi Ministry of Health Moi university
Kenya FELTP, Ministry of Health National Tuberculosis, leprosy and lung disease program, Burundi Bujumbura City Health Department Participants and interviewers
19
Thank you
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.